Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27821207 | 0.98 | CASP1 (0.96) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| Nitrogen SCHEMBL28460322 | 0.96 | CASP1 (0.92) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| SCHEMBL3204625 | 0.88 | CASP1 (0.78) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| SCHEMBL929312 | 0.88 | CASP1 (0.78) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| Hydrochloric Acid SCHEMBL23671046 | 0.86 | CASP1 (0.75) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| Hydrochloric Acid SCHEMBL5113010 | 0.86 | CASP1 (0.75) | CASP1CASP7HSD17B10HSD17B1MAOB | |
| SCHEMBL6658043 | 0.84 | CASP1 (0.71) | CASP1CASP7HSD17B10MAOBLMNA | |
| SCHEMBL30513596 | 0.83 | CASP1 (0.70) | CASP1CASP7HSD17B10MAOBLMNA | |
| SCHEMBL460333 | 0.83 | CASP1 (0.70) | CASP1CASP7HSD17B10MAOBLMNA | |
| Hydrochloric Acid SCHEMBL6571959 | 0.81 | CASP1 (0.67) | CASP1CASP7HSD17B10HSD17B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2595966-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | Onyx Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | claimed |
| EP-2268144-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | Bayer CropScience AG (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20100081679-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-04-01 | — | — | US | claimed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2010025871-A1 | 4-HALOGEN ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES FOR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2161259-A1 | 4-Haloalkyl substituted Diaminopyrimidine | Bayer CropScience AG (DE) | 2010-03-10 | — | — | EP | claimed |
| CN-101621927-A | Diaminopyrimidines as fungicides | BAYER CROPSCIENCE AG | 2010-01-06 | — | — | CN | claimed |
| EP-2129222-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2009-12-09 | — | — | EP | claimed |
| WO-2009115267-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2009-09-24 | — | — | WO | claimed |
| WO-2008107096-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2008-09-12 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-24 | — | — | US | disclosed |
| CN-117229244-A | Orange ketone analogue and application thereof | 中国科学院新疆理化技术研究所 | 2023-12-15 | — | — | CN | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| CN-116528648-A | Novel high-efficiency perovskite solar cell device structure and preparation method thereof | 华南理工大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-112759549-B | 3-substituted amino-4- ((substituted pyridinyl) amino) cyclobut-3-ene-1, 2-dione compounds | 中国医学科学院药物研究所 | 2023-07-28 | — | — | CN | disclosed |
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116003397-B | Benzo-polycyclic thiazoline amide compound and application thereof | 凯思凯旭(上海)医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4175658-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | Bridgene Biosciences, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-116003397-A | Benzo-polycyclic thiazoline amide compound and application thereof | 凯思凯旭(上海)医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4161930-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-110386927-B | Histone Acetyltransferase (HAT) inhibitors and uses thereof | 中国科学院上海药物研究所 | 2022-09-23 | — | — | CN | disclosed |
| CN-114163374-A | Dendritic macromolecule and preparation method and application thereof | 中国科学技术大学 | 2022-03-11 | — | — | CN | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| WO-2022006548-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006548-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| EP-3447045-B9 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-07-21 | — | — | EP | disclosed |
| CN-112759549-A | 3-substituted amino-4- ((substituted pyridyl) amino) cyclobut-3-ene-1, 2-diones | 中国医学科学院药物研究所 | 2021-05-07 | — | — | CN | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| US-10954178-B1 | Synthesis of haloindenes | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954178-B1 | Synthesis of haloindenes | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3447045-B1 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-03-03 | — | — | EP | disclosed |
| CN-107793363-B | Substituted arylamino aromatic heterocyclic compound and application thereof as antitumor drug | 上海医药工业研究院 | 2021-02-26 | — | — | CN | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| CN-108558627-B | Method for preparing 5-hydroxy-1-indanone | 山西大学 | 2020-09-29 | — | — | CN | disclosed |
| CN-110386927-A | Histone acetyltransferase (HAT) inhibitor and application thereof | 中国科学院上海药物研究所 | 2019-10-29 | — | — | CN | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190127320-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-02 | — | — | US | disclosed |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| CN-108602805-A | Isoindoline, azaisoindoline, indenone and the dihydro azepine indone inhibitor of MNK1 and MNK2 | 效应治疗股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-3368530-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | Effector Therapeutics Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-107793363-A | A kind of substituted aromatic amines base heteroaromatic class compound and its application as antineoplastic | 上海医药工业研究院 | 2018-03-13 | — | — | CN | disclosed |
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| CN-105237416-A | Synthesis method of 5-aminoindanone | Hunan huateng pharmaceutical co ltd | 2016-01-13 | — | — | CN | disclosed |
| CN-105237416-A | Synthesis method of 5-aminoindanone | Hunan huateng pharmaceutical co ltd | 2016-01-13 | — | — | CN | disclosed |
| CN-105237416-A | Synthesis method of 5-aminoindanone | Hunan huateng pharmaceutical co ltd | 2016-01-13 | — | — | CN | disclosed |
| CN-104557940-A | BCR-ABL kinase inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2614054-B1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2155675-B1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8609676-B2 | 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2462123-B1 | 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2595966-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | Onyx Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2462123-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | Schering Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | disclosed |
| WO-2011017296-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2268144-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | Bayer CropScience AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-7863280-B2 | Substituted 2-pyridone derivatives, method for their preparation and their use as medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1910338-B1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010083617-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010083617-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | ONCALIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| US-7709508-B2 | (8R,10aS)-6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile; bone disorders | MERCK SHARP & DOHME (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100081679-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-1745047-B1 | PYRAZOLO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE ADENOSINE-A2A- RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| EP-2161259-A1 | 4-Haloalkyl substituted Diaminopyrimidine | Bayer CropScience AG (DE) | 2010-03-10 | — | — | EP | disclosed |
| EP-2155675-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | Provid Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| CN-101621927-A | Diaminopyrimidines as fungicides | BAYER CROPSCIENCE AG | 2010-01-06 | — | — | CN | disclosed |
| CN-100572364-C | Suppress pyrimidine and triazine that HIV duplicates | TIBOTEC PHARM LTD (IE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2129222-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2009-12-09 | — | — | EP | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009115267-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2009-09-24 | — | — | WO | disclosed |
| EP-2086925-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090163559-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2009-06-25 | — | — | US | disclosed |
| EP-1622912-B1 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511152-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| EP-2014285-A1 | NPYY5 antagonists | Shionogi&Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101305010-A | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2008-11-12 | — | — | CN | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442705-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2008-10-28 | — | — | US | disclosed |
| US-7442705-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2008-10-28 | — | — | US | disclosed |
| US-7442705-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2008-10-28 | — | — | US | disclosed |
| EP-1749822-B1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008107096-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| CN-101213190-A | Compounds and compositions useful as TPO mimetics | IRM LLC (BM) | 2008-07-02 | — | — | CN | disclosed |
| EP-1934228-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1802578-B1 | 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910338-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-16 | — | — | EP | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2007147578-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070281948-A1 | SUBSTITUTED 2-PYRIDONE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070249705-A1 | N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1827421-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1802578-A1 | 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| EP-1786770-A1 | N-(1-(2,3-DIHYDRO-1H-INDEN-5YL) -2-OXO-3-PYRROLIDINYL) -SULFONAMIDE DERIVATIVES FOR USE AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1597238-B1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARM LTD (IE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1597238-B1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARM LTD (IE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060194804-A1 | Hiv replication inhibiting pyrimidines and triazines | TIBOTEC BVBA | 2006-08-31 | — | — | US | disclosed |
| EP-1675844-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006062876-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006042638-A1 | 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-04-27 | — | — | WO | disclosed |
| CN-1751030-A | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARM LTD (IE) | 2006-03-22 | — | — | CN | disclosed |
| WO-2006027186-A1 | N-(1-(2,3-DIHYDRO-1H-INDEN-5YL) -2-OXO-3-PYRROLIDINYL) -SULFONAMIDE DERIVATIVES FOR USE AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1597238-A1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | Tibotec Pharmaceuticals Ltd. (IE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| EP-1098891-B1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| WO-2005042513-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | STERIX LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004074262-A1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-09-02 | — | — | WO | disclosed |
| US-6762188-B1 | INHIBITING THYMIDYLATE SYNTHASE; COLON, BREAST OR LUNG CARCINOMA | SMITHKLINE BEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| US-6716852-B2 | FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES | LES LABORATORIES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| EP-1199307-B1 | Pharmaceutically active benzoquinazoline compounds | WELLCOME FOUND (GB) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6642251-B1 | Antitumor, 2-indolinone derivatives | SUGEN, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-20030199510-A1 | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity | SUGEN, INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1255757-B1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INST NAT SANTE RECH MED (FR) | 2003-06-18 | — | — | EP | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | LES LABORATOIRES SERVIER (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-1289525-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2003-03-12 | — | — | EP | disclosed |
| US-6525072-B1 | Prevention and treatment of cellular disorders such as cancer | SUGEN, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| US-6462036-B1 | INHIBITING SIGNAL TRANSDUCTION BY MODULATING ACTIVITY OF RECEPTOR AND NONRECEPTOR TYROSINE AND SERINE/THREONINE KINASES TO REGULATE AND MODULATE ABNORMAL OR INAPPROPRIATE CELL PROLIFERATION, DIFFERENTIATION, OR METABOLISM | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1199307-A1 | Pharmaceutically active benzoquinazoline compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| WO-2001087846-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-11-22 | — | — | WO | disclosed |
| US-6306865-B1 | SYNTHASE INHIBITORS AND ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1127051-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| EP-1047691-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-6090941-A | Pharmaceutically active benzoquinazoline compounds | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000027822-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
| EP-0986545-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999031086-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999029666-A1 | ARYLPIPERAZINE AND ARYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998054159-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
| US-5663337-A | ENZYME, ANTITUMOR | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5661155-A | THYMIDYLATE SYNTHASE INHIBITOR; ADMINISTERING TO THE MAMMAL SUFFERING FROM LEUKEMIA OR TUMOR 2-(5-(((1,2-DIHYDRO-3-METHYL-1-OXOBENZO(F)QUINAZOLINE-9-YL) METHYL)AMINO)-1-OXO-2-ISOINDOLINYL)GLUTARIC ACID OR SALTS | GLAXO WELLCOME INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0535034-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
| US-4616013-A | INOTROPIC AND VASODILATOR ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-07 | — | — | US | disclosed |
| EP-0145236-A2 | Thiadiazinone compounds, process for their preparation, and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-19 | — | — | EP | disclosed |
| US-4250252-A | A DEVELOPMENT-INHIBITOR-RELEASING COMPOUND COMPRISING A 5-(SULFOAMIDO-1-INDANONE-2-YL)THIO-TETRAZOLE | AGFA-GEVAERT, A.G. (DE) | 1981-02-10 | — | — | US | disclosed |
| US-4250252-A | A DEVELOPMENT-INHIBITOR-RELEASING COMPOUND COMPRISING A 5-(SULFOAMIDO-1-INDANONE-2-YL)THIO-TETRAZOLE | AGFA-GEVAERT, A.G. (DE) | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (49 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CASP1 238/4885CASP7 930/4885HSD17B10 3317/4885 |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | CASP1 4017/4885CASP7 4215/4885HSD17B10 2768/4885 |
| US-20060194804-A1 | Hiv replication inhibiting pyrimidines and triazines | TYMS, UMPS, DUT | CASP1 1903/4885CASP7 2043/4885HSD17B10 3271/4885 |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | CASP1 1850/4885CASP7 2700/4885HSD17B10 3091/4885 |
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | CASP1 3773/4885CASP7 4769/4885HSD17B10 656/4885 |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | CASP1 1992/4885CASP7 1290/4885HSD17B10 158/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CASP1 1483/4885CASP7 1995/4885HSD17B10 2499/4885 |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | CASP1 117/4885CASP7 33/4885HSD17B10 445/4885 |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | CASP1 442/4885CASP7 1265/4885HSD17B10 2006/4885 |
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | GPER1, ESRRA, HSD17B11 | CASP1 3775/4885CASP7 2678/4885HSD17B10 338/4885 |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | CASP1 4116/4885CASP7 3414/4885HSD17B10 183/4885 |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | CASP1 1785/4885CASP7 2344/4885HSD17B10 3821/4885 |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | CASP1 1421/4885CASP7 2439/4885HSD17B10 126/4885 |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | CASP1 1839/4885CASP7 3318/4885HSD17B10 4263/4885 |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CASP1 1410/4885CASP7 1892/4885HSD17B10 2679/4885 |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | CASP1 1128/4885CASP7 1260/4885HSD17B10 1803/4885 |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD17B3 | CASP1 3688/4885CASP7 3140/4885HSD17B10 27/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | CASP1 4017/4885CASP7 4215/4885HSD17B10 2768/4885 |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | CASP1 2639/4885CASP7 2512/4885HSD17B10 3526/4885 |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | NEK9, NEK2, NEK3 | CASP1 1892/4885CASP7 1039/4885HSD17B10 1108/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | CASP1 1892/4885CASP7 1039/4885HSD17B10 1108/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | CASP1 100/4885CASP7 722/4885HSD17B10 2334/4885 |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | SCN1B, SCN1A, SCN4A | CASP1 359/4885CASP7 1604/4885HSD17B10 1045/4885 |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | CASP1 1892/4885CASP7 1039/4885HSD17B10 1108/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | CASP1 4255/4885CASP7 3227/4885HSD17B10 1274/4885 |
| US-20100081679-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | PM20D2, DDT, DDX41 | CASP1 560/4885CASP7 493/4885HSD17B10 2420/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | CASP1 278/4885CASP7 356/4885HSD17B10 3452/4885 |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | CASP1 1059/4885CASP7 2594/4885HSD17B10 3171/4885 |
| US-20090163559-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | CASP1 3997/4885CASP7 4246/4885HSD17B10 1159/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | CASP1 2989/4885CASP7 2843/4885HSD17B10 3579/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | CASP1 4386/4885CASP7 4450/4885HSD17B10 948/4885 |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | CASP1 3638/4885CASP7 3146/4885HSD17B10 4155/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | CASP1 3408/4885CASP7 2602/4885HSD17B10 3513/4885 |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | SCN1B, SCN1A, SCN4A | CASP1 339/4885CASP7 1584/4885HSD17B10 1042/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | CASP1 1541/4885CASP7 350/4885HSD17B10 2218/4885 |
| US-20190127320-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | CASP1 2368/4885CASP7 1868/4885HSD17B10 2937/4885 |
| US-20070281948-A1 | SUBSTITUTED 2-PYRIDONE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENT | PARP3, PARP1, PARP2 | CASP1 168/4885CASP7 362/4885HSD17B10 1534/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | CASP1 3874/4885CASP7 2722/4885HSD17B10 2201/4885 |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | CASP1 4116/4885CASP7 3414/4885HSD17B10 183/4885 |
| US-20070249705-A1 | N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors | F11, F12, TFPI | CASP1 369/4885CASP7 2401/4885HSD17B10 2719/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | CASP1 773/4885CASP7 1222/4885HSD17B10 1640/4885 |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | DDX41, DDX1, DDX5 | CASP1 148/4885CASP7 274/4885HSD17B10 4283/4885 |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | MME, ACE, ECE1 | CASP1 2532/4885CASP7 3289/4885HSD17B10 1543/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | CASP1 4221/4885CASP7 4748/4885HSD17B10 633/4885 |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | EP300, HDAC11, HDAC1 | CASP1 4116/4885CASP7 3414/4885HSD17B10 183/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CASP1 1504/4885CASP7 1844/4885HSD17B10 3236/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | CASP1 2210/4885CASP7 1477/4885HSD17B10 4186/4885 |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | IDH2, INA, IDH3A | CASP1 1665/4885CASP7 1053/4885HSD17B10 1658/4885 |
| US-20030199510-A1 | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity | MAP4K2, CKS2, MAP4K1 | CASP1 3662/4885CASP7 2274/4885HSD17B10 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.